Axel C Carlsson1, Anders Larsson2, Johanna Helmersson-Karlqvist2, Lars Lind2, Erik Ingelsson3, Tobias E Larsson4, Matteo Bottai5, Johan Sundström3, Johan Ärnlöv6. 1. Centre for Family Medicine, Department of Neurobiology, Care Sciences, and Society, Karolinska Institute, Huddinge, Sweden; Department of Medical Sciences, Molecular Epidemiology and Science for Life Laboratory, Uppsala University, Uppsala, Sweden; 2. Department of Medical Sciences, Uppsala University Hospital, Uppsala, Sweden; 3. Department of Medical Sciences, Molecular Epidemiology and Science for Life Laboratory, Uppsala University, Uppsala, Sweden; 4. Department of Clinical Science, Intervention, and Technology, and. 5. Division of Biostatistics, Institute of Environmental Medicine, Karolinska Institute, Stockholm, Sweden; and. 6. Department of Medical Sciences, Molecular Epidemiology and Science for Life Laboratory, Uppsala University, Uppsala, Sweden; School of Health and Social Studies, Dalarna University, Falun, Sweden johan.arnlov@medsci.uu.se.
Abstract
BACKGROUND AND OBJECTIVES: Kidney injury molecule-1 (KIM-1) has been suggested as a clinically relevant highly specific biomarker of acute kidney tubular damage. However, community-based data on the association between urinary levels of KIM-1 and the risk for cardiovascular mortality are lacking. This study aimed to investigate the association between urinary KIM-1 and cardiovascular mortality. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: This was a prospective study, using the community-based Uppsala Longitudinal Study of Adult Men (N=590; mean age 77 years; baseline period, 1997-2001; median follow-up 8.1 years; end of follow-up, 2008). RESULTS: During follow-up, 89 participants died of cardiovascular causes (incidence rate, 2.07 per 100 person-years at risk). Models were adjusted for cardiovascular risk factors (age, systolic BP, diabetes, smoking, body mass index, total cholesterol, HDL cholesterol, antihypertensive treatment, lipid-lowering treatment, aspirin treatment, and history of cardiovascular disease) and for markers of kidney dysfunction and damage (cystatin C-based eGFR and urinary albumin/creatinine ratio). Higher urinary KIM-1/creatinine (from 24-hour urine collections) was associated with a higher risk for cardiovascular mortality (hazard ratio per SD increase, 1.27; 95% confidence interval [95% CI], 1.05 to 1.54; P=0.01). Participants with a combination of high KIM-1/creatinine (upper quintile, ≥175 ng/mmol), low eGFR (≤60 ml/min per 1.73 m(2)), and microalbuminuria/macroalbuminuria (albumin/creatinine ratio≥3 g/mol) had a >8-fold increased risk compared with participants with low KIM-1/creatinine (<175 ng/mmol), normal eGFR (>60 ml/min per 1.73 m(2)), and normoalbuminuria (albumin/creatinine ratio<3 g/mol) (hazard ratio, 8.56; 95% CI, 4.17 to 17.56; P<0.001). CONCLUSIONS: These findings suggest that higher urinary KIM-1 may predispose to a higher risk of cardiovascular mortality independently of established cardiovascular risk factors, eGFR, and albuminuria. Additional studies are needed to further assess the utility of measuring KIM-1 in the clinical setting.
BACKGROUND AND OBJECTIVES:Kidney injury molecule-1 (KIM-1) has been suggested as a clinically relevant highly specific biomarker of acute kidney tubular damage. However, community-based data on the association between urinary levels of KIM-1 and the risk for cardiovascular mortality are lacking. This study aimed to investigate the association between urinary KIM-1 and cardiovascular mortality. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: This was a prospective study, using the community-based Uppsala Longitudinal Study of Adult Men (N=590; mean age 77 years; baseline period, 1997-2001; median follow-up 8.1 years; end of follow-up, 2008). RESULTS: During follow-up, 89 participants died of cardiovascular causes (incidence rate, 2.07 per 100 person-years at risk). Models were adjusted for cardiovascular risk factors (age, systolic BP, diabetes, smoking, body mass index, total cholesterol, HDL cholesterol, antihypertensive treatment, lipid-lowering treatment, aspirin treatment, and history of cardiovascular disease) and for markers of kidney dysfunction and damage (cystatin C-based eGFR and urinary albumin/creatinine ratio). Higher urinary KIM-1/creatinine (from 24-hour urine collections) was associated with a higher risk for cardiovascular mortality (hazard ratio per SD increase, 1.27; 95% confidence interval [95% CI], 1.05 to 1.54; P=0.01). Participants with a combination of high KIM-1/creatinine (upper quintile, ≥175 ng/mmol), low eGFR (≤60 ml/min per 1.73 m(2)), and microalbuminuria/macroalbuminuria (albumin/creatinine ratio≥3 g/mol) had a >8-fold increased risk compared with participants with low KIM-1/creatinine (<175 ng/mmol), normal eGFR (>60 ml/min per 1.73 m(2)), and normoalbuminuria (albumin/creatinine ratio<3 g/mol) (hazard ratio, 8.56; 95% CI, 4.17 to 17.56; P<0.001). CONCLUSIONS: These findings suggest that higher urinary KIM-1 may predispose to a higher risk of cardiovascular mortality independently of established cardiovascular risk factors, eGFR, and albuminuria. Additional studies are needed to further assess the utility of measuring KIM-1 in the clinical setting.
Authors: Michael Haase; Prasad Devarajan; Anja Haase-Fielitz; Rinaldo Bellomo; Dinna N Cruz; Gebhard Wagener; Catherine D Krawczeski; Jay L Koyner; Patrick Murray; Michael Zappitelli; Stuart L Goldstein; Konstantinos Makris; Claudio Ronco; Johan Martensson; Claes-Roland Martling; Per Venge; Edward Siew; Lorraine B Ware; T Alp Ikizler; Peter R Mertens Journal: J Am Coll Cardiol Date: 2011-04-26 Impact factor: 24.094
Authors: Michael G Shlipak; Kunihiro Matsushita; Johan Ärnlöv; Lesley A Inker; Ronit Katz; Kevan R Polkinghorne; Dietrich Rothenbacher; Mark J Sarnak; Brad C Astor; Josef Coresh; Andrew S Levey; Ron T Gansevoort Journal: N Engl J Med Date: 2013-09-05 Impact factor: 91.245
Authors: Vishal S Vaidya; Monika A Niewczas; Linda H Ficociello; Amanda C Johnson; Fitz B Collings; James H Warram; Andrzej S Krolewski; Joseph V Bonventre Journal: Kidney Int Date: 2010-10-27 Impact factor: 10.612
Authors: Kevin Damman; Dirk J Van Veldhuisen; Gerjan Navis; Vishal S Vaidya; Tom D J Smilde; B Daan Westenbrink; Joseph V Bonventre; Adriaan A Voors; Hans L Hillege Journal: Heart Date: 2010-08 Impact factor: 5.994
Authors: Elisabet Nerpin; Erik Ingelsson; Ulf Risérus; Johan Sundström; Anders Larsson; Elisabeth Jobs; Magnus Jobs; Stein Hallan; Björn Zethelius; Lars Berglund; Samar Basu; Johan Arnlöv Journal: Nephrol Dial Transplant Date: 2011-02-18 Impact factor: 5.992
Authors: Johanna Helmersson-Karlqvist; Anders Larsson; Axel C Carlsson; Per Venge; Johan Sundström; Erik Ingelsson; Lars Lind; Johan Arnlöv Journal: Atherosclerosis Date: 2013-01-18 Impact factor: 5.162
Authors: Mark J Sarnak; Ronit Katz; Anne Newman; Tamara Harris; Carmen A Peralta; Prasad Devarajan; Michael R Bennett; Linda Fried; Joachim H Ix; Suzanne Satterfield; Eleanor M Simonsick; Chirag R Parikh; Michael G Shlipak Journal: J Am Soc Nephrol Date: 2014-02-07 Impact factor: 10.121
Authors: G Gulati; M R Bennett; K Abulaban; H Song; X Zhang; Q Ma; S V Brodsky; T Nadasdy; C Haffner; K Wiley; S P Ardoin; P Devarajan; J Ying; B H Rovin; H I Brunner Journal: Lupus Date: 2016-12-19 Impact factor: 2.911
Authors: Dominik Steubl; Petra Buzkova; Pranav S Garimella; Joachim H Ix; Prasad Devarajan; Michael R Bennett; Paulo H M Chaves; Michael G Shlipak; Nisha Bansal; Mark J Sarnak Journal: Nephrol Dial Transplant Date: 2020-08-01 Impact factor: 5.992
Authors: Alexandra K Lee; Ronit Katz; Vasantha Jotwani; Pranav S Garimella; Walter T Ambrosius; Alfred K Cheung; Lisa H Gren; Javier A Neyra; Henry Punzi; Kalani L Raphael; Michael G Shlipak; Joachim H Ix Journal: Hypertension Date: 2019-08-05 Impact factor: 10.190
Authors: Sylwia M Figarska; Stefan Gustafsson; Johan Sundström; Johan Ärnlöv; Anders Mälarstig; Sölve Elmståhl; Tove Fall; Lars Lind; Erik Ingelsson Journal: Arterioscler Thromb Vasc Biol Date: 2018-10 Impact factor: 8.311
Authors: Nisha Bansal; Myra A Carpenter; Daniel E Weiner; Andrew S Levey; Marc Pfeffer; John W Kusek; Jianwen Cai; Lawrence G Hunsicker; Meyeon Park; Michael Bennett; Kathleen D Liu; Chi-Yuan Hsu Journal: J Am Soc Nephrol Date: 2015-11-04 Impact factor: 10.121
Authors: Aleksandra Tonkonogi; Axel C Carlsson; Johanna Helmersson-Karlqvist; Anders Larsson; Johan Ärnlöv Journal: Ups J Med Sci Date: 2016-06-20 Impact factor: 2.384
Authors: Axel C Carlsson; Christoph Nowak; Lars Lind; Carl Johan Östgren; Fredrik H Nyström; Johan Sundström; Juan Jesus Carrero; Ulf Riserus; Erik Ingelsson; Tove Fall; Johan Ärnlöv Journal: Ups J Med Sci Date: 2019-12-05 Impact factor: 2.384
Authors: Lars Wallentin; Niclas Eriksson; Maciej Olszowka; Tanja B Grammer; Emil Hagström; Claes Held; Marcus E Kleber; Wolfgang Koenig; Winfried März; Ralph A H Stewart; Harvey D White; Mikael Åberg; Agneta Siegbahn Journal: PLoS Med Date: 2021-01-13 Impact factor: 11.069